Executive summary of the expert consensus document from the Spanish Society of Neurosurgery and the Spanish Society of Endocrinology and Nutrition: Clinical recommendations on the perioperative management of pituitary tumors

Pituitary tumors (PT) account for 15% of intracranial tumors affect 10.7 to 14.4% of the population although the incidence of clinically relevant PT is 5.1 cases/100,000 inhabitants. Surgical treatment is indicated in PTs with hormone hypersecretion (except for prolactin-producing PTs) and those with local compressive or global neurological symptoms. Multidisciplinary care, is essential for patients with PTs, preferably delivered in a center of excellence and based on a well-defined care protocol. In order to facilitate and standardize the clinical procedures for this type of tumor, this document gathers the positioning of the Neuroendocrinology Knowledge Area of the Spanish Society of Endocrinology and Nutrition (SEEN) and the Spanish Society of Neurosurgery (SENEC) on the management of patients with PTs and their preoperative, surgical and postoperative follow-up. (c) 2023 Sociedad Espanola de Endocrinologia y Nutricion y Sociedad Espanola de Diabetes and Sociedad Espanola de Neurocirugia. Published by Elsevier Spain on behalf of Sociedad Espanola de Endocrinologia y Nutricion y Sociedad Espanola de Diabetes and Sociedad Espanola de Neurocirugia All rights reserved.

Automated summary

Pituitary tumors, accounting for 15% of intracranial tumors, require surgical treatment for hormone hypersecretion and neurological symptoms. Multidisciplinary care is crucial and should be delivered in a center of excellence with a well-defined care protocol.